Original Query: ALL
Previous Study | Return to List | Next Study

A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near Vision in Presbyopic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01373580
Recruitment Status : Completed
First Posted : June 15, 2011
Last Update Posted : January 10, 2017
Information provided by (Responsible Party):
ReVision Optics, Inc.

Brief Summary:
This study will be a prospective, multicenter clinical trial in which a total of 400 subjects will be enrolled. All subjects will be followed over a 36 month time frame with a maximum of 15 clinical sites participating. Qualified subjects will provide informed consent for entry into the study.

Condition or disease Intervention/treatment Phase
Presbyopia Device: The Raindrop Near Vision Inlay Phase 3

Detailed Description:

The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. This natural transformation in the eye occurs as a result of the loss of accommodation of the crystalline lens, a condition known as presbyopia. Presbyopia, characterized by a progressive, age-related loss of accommodation (i.e., the lens ability to focus clearly over a wide range of distances), is most prevalent of all visual deficiencies, affecting 100% of the population over the course of a normal life span. Loss of accommodation begins early in life and, for an emmetropic eye, generally culminates in a complete loss of functional near vision.

ReVision Optics has developed the Raindrop corneal inlay for the correction of near vision. The Raindrop is a 2mm corneal inlay, as small as a pinhead, thinner than a human hair and about 1/500th of a droplet of water. The inlay is the same refractive index as the human cornea. The inlay is placed in the non-dominant eye,centered over the pupil after a corneal flap (LASIK)has been made. The Raindrop is expected to provide presbyopic subjects with improvement of near and intermediate vision.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 373 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multinational Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc. PresbyLens Corneal Inlay for the Improvement of Near Vision in Presbyopic Subjects With MRSE From -0.50 to +1.00
Study Start Date : April 2010
Primary Completion Date : December 2016
Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Raindrop
A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
Device: The Raindrop Near Vision Inlay
The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
Other Name: Presbylens

Primary Outcome Measures :
  1. Improvement in uncorrected near visual acuity [ Time Frame: 24 Months ]
    75% of eyes should achieve uncorrected near visual acuity of 20/40 or better

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

must be presbyopic adults, needing from +1.50 to +2.50 or reading add must have uncorrected near visual acuity worse than 20/40 and better than 20/200in the eye to be implanted must have an uncorrected distance visual acuity of 20/25 or better in both eyes must have a distance visual acuity correctable to 20/20 in both eyes must have a near visual acuity correctable to 20/20 in both eyes must have a manifest refraction spherical equivalent between -0.50 and +1.00D in the eye to be implanted with no more than 0.75D of refractive cylinder must report stable vision, i.e. no change in distance vision and or MRSE within 0.50D over prior 12 months must discontinue hard or rigid gas permeable lenses for at least 3 weeks and discontinue soft lenses for at least 1 week prior to baseline examination must have a minimum central corneal thickness of >500 microns in the eye to be implanted must have a mesopic pupil < 7.0mm and photopic pupil >3.0mm in the eye to be implanted subjects aged 45 years or younger must have an endothelial cell count

Exclusion Criteria:

Subjects with a difference of >0.75 between the manifest refraction spherical equivalent and the cycloplegic refraction spherical equivalent Subjects with anterior segment pathology, including clinically significant cataracts, in the non-dominant eye Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormality (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in the non-dominant eye Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the non-dominant eye Subjects with clinically significant dry eyes, as determined by either the presence of greater than mild symptoms of dryness or discomfort or SPK greater than grade 1 Subjects with distorted or unclear mires on topography maps of the non-dominant eye Subjects with macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in the non-dominant eye Subjects who have undergone LASIK surgery in the non-dominant eye Subjects with a history of herpes zoster or herpes simplex keratitis Subjects who have a history of steroid responsive rise in intraocular pressure, pre-operative IOP>21 mm Hg, glaucoma or are a glaucoma suspect Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue disease, or clinically significant atopic syndrome Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immunocompromised subjects Subjects who are using ophthalmic mediation(s) other than artificial tears for treatment of any ocular pathology Subjects using systemic medications with significant ocular side effects Subjects who are pregnant, lactating, or planning to become pregnant during the course of the study Subjects what are participating in any other ophthalmic drug or device studies during the time of this clinical investigation Subjects with known sensitivity to planned study concomitant medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01373580

United States, California
Dougherty Laser Vision
Camarillo, California, United States, 93010
Harvard Eye Associates
Laguna Hills, California, United States, 92653
Coastal Vision
Newport Beach,, California, United States, 92660
United States, Colorado
Jon G. Dishler, M.D.
Greenwood Village, Colorado, United States, 80111
United States, Hawaii
Eyesight Hawaai
Honolulu, Hawaii, United States, 96816
United States, Minnesota
Chu Vision
Bloomington, Minnesota, United States, 55420
United States, Texas
Key-Whitman Eye Center
Dallas, Texas, United States, 75204
Carter Eye Center
Dallas, Texas, United States, 75205
Slade and Baker Vision Center
Houston, Texas, United States, 77027
Lehmann Eye Center
Nacogdoches, Texas, United States, 75965
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
ReVision Optics, Inc.
Principal Investigator: Steven G Slade, M.D.
Principal Investigator: Jon G Dishler, MD
Principal Investigator: John Olkowski, M.D.
Principal Investigator: Dan B Tran, M.D.
Principal Investigator: Ralph Y Chu, M.D.
Principal Investigator: Jeffrey Whitman, M.D.
Principal Investigator: Robert P Lehmann, M.D.
Principal Investigator: Gregory Parkhurst, M.D Unaffilliated
Principal Investigator: Harvey L Carter, III, M.D. Unaffilliated
Principal Investigator: Paul Dougherty, M.D. Unaffilliated
Principal Investigator: John Hovanesian, M.D. Unaffilliated

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: ReVision Optics, Inc. Identifier: NCT01373580     History of Changes
Other Study ID Numbers: P09-0003
First Posted: June 15, 2011    Key Record Dates
Last Update Posted: January 10, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by ReVision Optics, Inc.:
loss of accommodation

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases